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Abstract: Objective:   interstage mortality after Norwood stage-one operation remains 12-20% in
current series. In-hospital interstage facilitates escalation of care, possibly improving
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outcome.
Methods:    retrospective study designed for HLHS and HLHS-variants, offering in-
hospital stay after Norwood operation until stage-two completion. Daily and weekly
investigations were systematically conducted, including 2-D and speckle-tracking
echocardiography.  Primary end-points included aggregate survival until stage-two
completion and interstage freedom from escalation of care. Secondary end-point
calculated sensitivity and specificity of speckle-tracking echocardiographic RV
deformation in predicting death/transplant after Norwood.
Results:     between 2015 and 2019, 33 neonates with HLHS (24) or HLHS-variants (9),
underwent Norwood stage-one (31) or hybrid-palliation followed by comprehensive
stage-two operation (2).  Stage-one Norwood-Sano was preferred in 18 (54.5%), while
Norwood-BT shunt in 13 (39.4%). Norwood stage-one 30-day mortality was 6.2%. In-
hospital interstage was endorsed in 29/31 survivors (93.6%) with 3.4% interstage
mortality. Aggregate Norwood stage-one and interstage KM-survival was 90.6±5.2%.
Escalation of care was necessary in 5 (17.2%) at 2.5±1.2 months during interstage for
compromising atrial arrhythmias (2), Sano-shunt stenosis (1) and pneumonia requiring
high-frequency oscillator (2), with no mortality. Bidirectional-Glenn (25) or
comprehensive-Norwood stage-two (2) were completed in 27 patients at 4.7±1.2
months with 92.6% survival. Overall KM-survival is 80.9±7.0% at 4.3 years (mean
25.3±15.7 months). An 8.7% Δ longitudinal strain 30 days after Norwood stage-one
had 100% sensitivity and 81% specificity for death/transplant.
Conclusions:    in-hospital interstage facilitates escalation of care, which seems
efficacious in reducing interstage Norwood mortality. Significant reduction of
longitudinal strain after Norwood stage-one is a strong predictor of poor outcome.
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(uncensored) and the contribution to interstage follow-up was deleted at this time.
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Objective:  interstage mortality after Norwood stage-one operation remains 12-20% in current series. 3 
In-hospital interstage facilitates escalation of care, possibly improving outcome. 4 
Methods:   retrospective study designed for HLHS and HLHS-variants, offering in-hospital stay after 5 
Norwood operation until stage-two completion. Daily and weekly investigations were systematically 6 
conducted, including 2-D and speckle-tracking echocardiography.  Primary end-points included 7 
aggregate survival until stage-two completion and interstage freedom from escalation of care. 8 
Secondary end-point calculated sensitivity and specificity of speckle-tracking echocardiographic RV 9 
deformation in predicting death/transplant after Norwood. 10 
Results:    between 2015 and 2019, 33 neonates with HLHS (24) or HLHS-variants (9), underwent 11 
Norwood stage-one (31) or hybrid-palliation followed by comprehensive stage-two operation (2).  12 
Stage-one Norwood-Sano was preferred in 18 (54.5%), while Norwood-BT shunt in 13 (39.4%). 13 
Norwood stage-one 30-day mortality was 6.2%. In-hospital interstage was endorsed in 29/31 survivors 14 
(93.6%) with 3.4% interstage mortality. Aggregate Norwood stage-one and interstage KM-survival was 15 
90.6±5.2%. Escalation of care was necessary in 5 (17.2%) at 2.5±1.2 months during interstage for 16 
compromising atrial arrhythmias (2), Sano-shunt stenosis (1) and pneumonia requiring high-frequency 17 
oscillator (2), with no mortality. Bidirectional-Glenn (25) or comprehensive-Norwood stage-two (2) 18 
were completed in 27 patients at 4.7±1.2 months with 92.6% survival. Overall KM-survival is 19 
80.9±7.0% at 4.3 years (mean 25.3±15.7 months). An 8.7% Δ longitudinal strain 30 days after Norwood 20 
stage-one had 100% sensitivity and 81% specificity for death/transplant. 21 
Conclusions:  in-hospital interstage facilitates escalation of care, which seems efficacious in reducing 22 
interstage Norwood mortality. Significant reduction of longitudinal strain after Norwood stage-one is 23 





Interstage mortality after Norwood stage-one operation for hypoplastic left heart syndrome (HLHS) 2 
and HLHS-variants remains between 12% and 20% in most reported series despite close surveillance 3 
[1]. This attrition essentially presents as sudden death at home and is predominantly related to the 4 
intrinsic fragility of the parallel model of Norwood stage-one circulation [2]. Shunt take-down and 5 
creation of a cavopulmonary anastomosis converts the frail parallel circulation to the more stable in-6 
series circulation model of Norwood stage-two.  Home-monitoring (HMP) with daily detection of 7 
peripheral oxygen-saturation level and weight change has been advocated by Rudd et al. [3] to 8 
neutralize the adverse events, with an excellent 2% interstage mortality. However, this unique 9 
experience has not been confirmed by others. The multicenter Single Ventricle Reconstruction (SVR) 10 
trial reported an 18 % interstage mortality after Norwood stage-one with modified BT-shunt despite 11 
HMP [1], while the National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) study 12 
failed to identify any associations of home oxygen-saturation or weight monitoring with mortality or 13 
readmission during interstage [4]. The interstage between Norwood stage-one and Norwood stage-14 
two remains a vulnerable transition which might justify an alternative strategy to current HMP. This 15 
study evaluates the efficacy of a preliminary experience with a systematic HLHS-dedicated in-hospital 16 
interstage program (in-HIP).   17 
Methods 18 
Ethical statement 19 
The NHS National Ethical review approved this study as UK Health Research Authority project ID 20 
235600, reference 17/EE/0417. 21 
A retrospective single-centre study was conducted at the Royal Brompton Hospital including all 22 
patients with diagnosis of HLHS or HLHS-variants undergoing Norwood stage-one palliation.  The 23 
distinctive feature of this investigation was to implement in-HIP after Norwood stage-one operation 24 
[5] 
 
until completion of Norwood stage-two. This strategy was introduced in June 2015 and we reviewed 1 
outcome until current date. The rationale for in-HIP was to maximize escalation of care as prompt 2 
response to cardiac or extra-cardiac adverse events, while boosting interstage screening.  Interstage 3 
was defined as the time interval between the patient’s discharge from the paediatric intensive care 4 
unit (PICU) to the regular ward, until Norwood stage-two completion. Escalation of care was defined 5 
as the need for PICU re-admission from the regular ward due to cardiac or extracardiac life-6 
threatening events occurring during in-HIP and requiring intensive medical/respiratory care or 7 
reintervention.  During in-HIP daily and weekly investigational plans were systematically 8 
implemented. Telemetry and peripheral oxygen-saturation were monitored, while precise intake and 9 
vital signs were detected every 8 hours. Weight change was traced on daily basis. ECG, troponin, BNP 10 
and 2D echocardiography were performed on a weekly basis or earlier if clinically indicated. Beyond 11 
the usual echocardiographic parameters, the tricuspid annulus peak systolic excursion (TAPSE), 12 
fractional area change (FAC), longitudinal strain (LS) and strain rate (LSR) were measured from the 13 
apical view at specific time intervals: baseline pre-Norwood, one-month after Norwood stage-one, 14 
one-week prior to Norwood stage-two and two-months after hospital discharge following Norwood 15 
stage-two completion.  A ∆ LS was defined by [{baseline LS – post Norwood LS}/ baseline LS] *100). 16 
Based on clinical outcomes, these parameters were compared between Norwood transplant-free 17 
survivors and Norwood failures (including non-survivors or heart transplant). The two primary end-18 
points of this research evaluated the aggregate transplant-free survival (including Norwood stage-one, 19 
in-hospital interstage and Norwood stage-two) and the freedom from escalation of care during in-HIP. 20 
As secondary endpoint, this study calculated the sensitivity and specificity of speckle-tracking 21 
echocardiographic assessment of RV deformation in predicting death or transplant after Norwood 22 





Statistical analysis 1 
Standard summary statistics were reported as mean and standard deviation for normally distributed 2 
continuous variables, while medians with interquantile ranges were used for skewed continuous 3 
variables. The Kolmogorov–Smirnov method was used to test normality for each variable. Categorical 4 
analysis was conducted by Fisher’s exact testing, while continuous variables were compared by 5 
unpaired t-testing or Mann-Whitney test when appropriate. Analysis of freedom from events (death, 6 
transplant or reintervention) at different standpoints during surgical staging was conducted by Kaplan-7 
Meier technique. Cumulative hazard was calculated for each event-free survival. The 8 
echocardiographic parameters assessing RV function were evaluated as potential risk factors for 9 
Norwood failures by logistic analysis, and then entered in a multivariable stepwise regression model 10 
to identify the independent predictors of the combined outcome death/heart transplant during 11 
Norwood staging. Operating characteristic curves (ROC) were finally plotted calculating the areas 12 
under the curves (AUCs) in order to verify sensitivity and specificity of the independent predictors of 13 
Norwood failure. Statistical analysis was performed with MedCalc, version 18.11 (MedCalc Software, 14 
Mariakerke, Belgium) and SPSS version 23.0 (SPSS, Chicago, IL). 15 
Results 16 
Since June 2015, 33 consecutive patients (19 males and 14 females) underwent Norwood stage-one 17 
operation (31 patients) or hybrid approach (bilateral pulmonary artery banding and ductal stenting) 18 
followed by comprehensive stage-two (2 patients). In-HIP was implemented after Norwood stage-one 19 
procedure. Prenatal diagnosis was available in 29 (93.5%). HLHS was the predominant diagnosis (24 20 
patients, 77.4%). Anatomic details and associated lesions are depicted in Table 1. No patient’s 21 
selection was applied, accepting referrals with HLHS and associated lesions (8/31=25.8) including 22 




Norwood stage-one  1 
A Norwood stage-one operation was performed at 3.4±2.1 day of life, and 3.1±0.4 kg mean body 2 
weight. Two premature babies (<37 weeks gestation) and 2.4 Kg body weight were initially palliated 3 
by bilateral PA-banding while continuing PGE1 infusion until Norwood operation at 2 weeks of life. 4 
There was a slight preference for the Norwood-Sano modification (54.5%) versus the classic Norwood 5 
operation with RmBT-shunt (39.4%), with a strong correlation between Norwood-Sano and aortic 6 
diameter ≤ 2.0 mm  (Fisher exact-testing p-value <0.01, Х216.1). Shunt size was uniformly 5.0 mm for 7 
the Sano modification and 3.5 mm for the classic Norwood operation with RmBT-shunt. Associated 8 
procedures concomitant with Norwood stage-one included repair of TAPVC, exclusion of a hypoplastic 9 
but severely regurgitant mitral valve and patch exclusion of an absent aortic valve. The nomogram of 10 
surgical strategy is depicted in Figure 1. Thirty-day mortality was 6.4% (2 patients). One patient died 11 
19 days after Norwood-Sano operation because of intractable heart failure due to early development 12 
of multiple aorto-pulmonary collaterals (APC). ECMO was instituted on 16th postoperative-day and 13 
subsequent cardiac catheterization demonstrated 5 large APC mainly for the right lung. Effective 14 
coiling of all APC was achieved but ventricular function did not recover, and mechanical support 15 
discontinued. The second postoperative death was secondary to ANCA-associated vasculitis with 16 
systemic vasospasm and pulmonary alveolar hemorrhage at 5 days after Norwood-Sano operation. 17 
ECMO support was ineffective. Microscopic polyangiitis was detected at postmortem examination. 18 
Complications after Norwood stage-one are described in Table 2. The 30-day survival was 93.3±4.6%. 19 
Mean combined ICU/HDU stay after Norwood stage-one was 42.3±6.4 days. 20 
Interstage 21 
All 29 Norwood-survivors were followed closely after transfer to the ward until Norwood stage-two 22 
completion, according to the daily and weekly protocol described. Mean in-HIP duration was 3.3±1.4 23 
months. Medical therapy included a systematic combination of diuretics (furosemide and 24 
spironolactone) and vasodilators (captopril or enoximone). Digoxin was administered frequently 25 
[8] 
 
(57.1%) while b-blockers were used seldom during interstage (7.4%). One patient died at 4.07 months 1 
during in-HIP, accounting for a 3.4% in-HIP mortality. Cause of death was progressive diastolic 2 
dysfunction leading to ventricular failure. Persistently high O2 saturation exceeding 90% after a 3 
classic-Norwood operation prompted a cardiac catheterization at 3 months of age, which detected 4 
multiple APC and elevated EDP (18 mmHg). Despite APC coiling and maximal medical therapy, EDP did 5 
not improve and the patient was not considered a candidate for Norwood stage-two. Nine patients 6 
(31%) required further surgical (2) or catheter (7) reintervention during in-HIP.  Two unplanned 7 
reoperations were performed during in-HIP (6.8%). The first unplanned surgery was indicated to repair 8 
a progressively incompetent neo-aortic valve, detected at serial postoperative echocardiograms after 9 
Norwood-Sano operation. Although clinically tolerated, the increment in vena-contracta prompted 10 
reoperation at 1.5 months after initial Norwood stage-one. The anterior left cusp of the neo-aortic 11 
valve was found to be retracted, generating an eccentric jet. The neoaortic-valve was repaired by 12 
augmenting the retracted cusp with a pulmonary homograft leaflet patch. Valve continence was 13 
restored with uneventful recovery and long-term efficacy. This patient recently underwent successful 14 
fenestrated extracardiac-Fontan completion and his perfect neo-aortic valve competence was 15 
documented at intraoperative TOE.  Persistent non-invasive ventilation dependency prompted CT-16 
angiography in another patient, 3.2 months after classic-Norwood operation complicated by Gram-17 
negative mediastinitis. Despite control of the infection and good healing of the sternotomy wound, 18 
respiratory symptoms were investigated. A rapidly expanding pseudo-aneurysm compressing the left 19 
pulmonary artery and the left bronchus was confirmed at two consecutive CT-angiograms, prompting 20 
urgent reoperation. A pulmonary homograft patch was utilized to reconstruct and repair the ventral 21 
portion of the aortic arch, excluding the aneurysm, under deep hypothermic circulatory arrest. The 22 
procedure was well tolerated, and 30-day control CT-angiogram confirmed proper arch anatomy and 23 
resolution of the arch aneurysm. Additional unplanned catheter interventions were indicated at 2.7± 24 
0.4 months during in-HIP in 7 patients (24.1%), to occlude multiple APC (4=13.8%), stent a stenotic 25 
Sano-shunt (1), balloon dilate a recurrent coarctation (1) and stent a compressed left pulmonary artery 26 
[9] 
 
(1). Freedom from any type of reintervention during in-HIP is depicted in Figure 2a. Five patients (17.2) 1 
required escalation of care from ward to ICU at a mean 2.5±1.2 months during in-HIP.  De-novo 2 
multifocal narrow-complex atrial tachycardia developed at telemetry and was documented on ECG in 3 
two patients with no previous evidence of rhythm issues during in-HIP . These incidents proved to be 4 
hemodynamically compromising with hypotension and desaturation not responding to volume, 5 
electrolyte replacement or vagal maneuvers. Prompt echocardiographic assessment showed new 6 
onset of moderate-to-severe tricuspid valve incompetence and impaired ventricular function, 7 
compared with trivial tricuspid regurgitation and preserved ventricular function at multiple 8 
echocardiographic evaluations prior to the event. Both patients were immediately transferred to PICU 9 
where central IV access was gained after endotracheal intubation, and amiodarone infusion 10 
commenced after unsuccessful adenosine bolus and synchronized cardioversion. Resolution of the 11 
arrhythmia together with recovery of tricuspid valve and ventricular function was documented within 12 
72 hours of acute treatment. Both babies had an otherwise uneventful recovery on oral amiodarone, 13 
and successful Norwood stage-two operation was completed at 4.7 and 4.2 months of life respectively. 14 
Aspiration (1) or RSV pneumonia (1) were the reasons for escalation of care in two additional patients 15 
who required urgent PICU readmission and institution of high-frequency oscillatory ventilation. This 16 
and subsequent management proved to be successful in both cases with no sequelae. Both patients 17 
were converted to conventional ventilation and then extubated after resolution of the radiographic 18 
opacifications. Both were discharged from PICU to the ward 10 and 13 days after the incident. Sudden 19 
hypoxic spell on the ward was the presenting symptom of acute RV-to-PA conduit critical stenosis in 20 
another patient at 2.2 months of an otherwise unremarkable in-HIP. Cardiac catheterization was 21 
promptly organized after stabilization in PICU with endotracheal intubation, sedation and paralysis. A 22 
proximal dynamic stenosis on the RV take-off of the Sano conduit was identified and successfully 23 
stented with resolution of the hypoxemia.  In summary, endotracheal intubation was indicated in all 24 
cases requiring escalation of care. Mean time-interval between onset of the incident and endotracheal 25 
intubation was 25±8 minutes. Kaplan-Meier analysis showed a 90.6±5.2% aggregate Norwood stage-26 
[10] 
 
one and in-HIP survival (Figure 3), an 81.9±7.3% freedom from escalation of care during in-HIP and a 1 
63.3±6.9% freedom from any type of surgical or catheter-based reintervention during in-HIP (Figure 2 
2a and 2b), therefore confirming the intensive management required during in-HIP. During in-HIP all 3 
patients underwent speckle-tracking echocardiography at the previously specified time-intervals. 4 
Figure 4 depicts the significant decline of TAPSE, LS, ∆ LS and ∆ LSR at one-month evaluation in 5 
Norwood-failures (death or transplant at any time during follow-up), as opposed to a constant 6 
longitudinal trend in transplant-free Norwood survivors. A similar pattern was identified after 7 
Norwood stage-two. LS and TAPSE at one month after Norwood were identified as independent 8 
predictors of death/transplant at stepwise multivariable analysis (Table 3). TAPSE ≤ 5 mm at one-9 
month after Norwood stage-one showed 85.7% sensitivity and 66.7% specificity as predictive value 10 
for combined outcome death/transplant, with an AUC of 0.79.  ∆ LS (cut off > 8.7%) showed a 100% 11 
sensitivity and 81% specificity for death/transplant with an AUC of 0.89 (Figure 5).   12 
Parental social and psychological impact of in-HIP was evaluated with a survey in September 2019. 13 
Ninety-six % of parents defined in-HIP as extremely useful in relieving parental responsibility and 14 
pressure related to the care and monitoring of their HLHS-baby, who had siblings in 93%. Easy-access 15 
to parental hospital accommodation, psychology support and in-hospital social activities were 16 
unanimously well received. According to the comments in the survey, in-HIP allowed the parents to 17 
spend more quality-time out-of-hospital for adequate attention to their other children, knowing that, 18 
in their absence, their HLHS-baby was in the most secure place at the most vulnerable time of his/her 19 
life. 20 
Norwood stage-two  21 
Norwood stage-two was completed in 27 patients by means of a right (23), left (1), bi-lateral (1) bi-22 
directional Glenn (BDG) or comprehensive stage-two (2) at a mean age of 4.7±1.2 months. Three 23 
patients are currently alive and awaiting Norwood stage-two completion. No additional sources of 24 
pulmonary blood flow were maintained with stage-two and all RV-PA conduits or BT-shunts were 25 
[11] 
 
obliterated. Associated procedures with Norwood stage-two were common, mainly to augment the 1 
central pulmonary arteries (12), to repair the tricuspid valve (2), concurrently repair the tricuspid valve 2 
and augment the central pulmonary arteries (2) or to repair a PAPVC of the right superior and middle 3 
pulmonary veins to the right SVC (1).  Mortality after Norwood stage-two was 7.4% (2 patients). The 4 
cause of death in the first was right ventricular failure, which became unmasked after volume un-5 
loading by tricuspid valve repair. Medical management could not control the progressive deterioration 6 
of ventricular function prompting referral for heart transplantation. The patient died on the waiting 7 
list 3.8 months after Norwood stage-two. High PVR determined early failure of Norwood stage-two in 8 
the second patient, who had been ventilator-dependent since the initial Norwood stage-one 9 
operation. Treatment with pulmonary vasodilators including prostacyclin did not prove to be effective. 10 
BDG take-down with construction of a new BT-shunt was not considered feasible due to clotting of 11 
the pulmonary arterial system. One additional patient developed ventricular dysfunction secondary 12 
to progressive tricuspid regurgitation and hypoxemia (O2-saturation 60%), requiring multiple hospital 13 
readmissions after Norwood stage-two with tricuspid valve repair. She was referred for heart 14 
transplantation which was successfully performed 5.1 months after stage-two. There was no 15 
additional mortality between stage-two and Fontan completion 16 
Fontan completion  17 
Currently, an extracardiac fenestrated (4 mm) Fontan has been completed in 5 patients at a median 18 
age of 43 months with no mortality. The overall Kaplan-Meier transplant-free survival for the entire 19 
cohort is  80.9 ± 7.0% at 51 months (mean 25.3±15.7 months) (Figure 3).  20 
Discussion   21 
Despite major improvements occurred over the last two decades in prenatal diagnosis, surgical 22 
management and postoperative care of HLHS and HLHS-variants, the interstage between Norwood 23 
stage-one and stage-two palliation remains a time of notable morbidity and mortality. The Single-24 
Ventricle-Reconstruction trial, the largest multicenter prospective study published to date, reported 25 
[12] 
 
a 12% interstage mortality [1]. Noticeably this study highlighted an 18% interstage mortality for the 1 
classic-Norwood operation with RmBT-shunt [1]. These and similar findings support the inference that 2 
interstage mortality can be close or even higher than contemporary surgical mortality for Norwood 3 
stage-one operation [5]. Several risk factors have been identified as independent predictors of 4 
interstage mortality, including gestational age, ethnicity, census, anatomic subgroup, surgical 5 
technique, residual lesions, arrhythmias or acquired intercurrent illnesses [2]. HMP has been 6 
implemented as a key effort to improve interstage outcomes and consists of home oxygen-saturation 7 
monitoring and weight-checks. HMP ambition is to flag deteriorations in clinical conditions, with 8 
earlier detection possibly translating into improved outcomes [3,6,7]. Rudd [3] reported a significant 9 
reduction of interstage mortality from 16% to 2% over a 10-year HMP experience, compared with 10 
historical controls at Children’s Hospital of Wisconsin. With NPC-QIC implementation, HMP for HLHS 11 
has been widely adopted in the US and expanded to include all shunt-dependent single ventricles (SV-12 
HMP) [6,8]. A similar strategy has been endorsed by other non-US centers [9].  HMP is a complex 13 
endeavor that relies heavily on parental involvement and education, requires dedicated cardiac teams 14 
with specialist-nurses and cardiologists (among others) available 24 hours/day to triage all the events 15 
that result in breach of predetermined parameters, it involves frequent home visits, dedicated 16 
hospital clinics with outpatient or emergency-room evaluation by professionals familiar with HLHS 17 
management. Finally, when indicated, hospital admission must be organized whereby a pediatric ICU 18 
and HLHS expertise is available. Interestingly most centers report 60% hospital readmission rate at 19 
least once during HMP interstage, with 85% flagged home-events requiring in-hospital evaluation 20 
[3,10]. These findings essentially underline the interstage vulnerability status.  Despite this intensive 21 
effort, some concerns have emerged regarding HMP efficacy.  On a large multicenter study, Oster et 22 
al. [4], on behalf of the NPC-QIC, failed to demonstrate any benefit of interstage daily home-oxygen 23 
or weight-monitoring regarding reduced interstage mortality, transplantation, unscheduled clinic 24 
visits, or unplanned readmissions. Oster reported 8.1% interstage HLHS mortality, lower than in 25 
previous cohorts, suggesting an improved overall care coordination independent of HMP. Oster 26 
[13] 
 
recommended further efforts beyond HMP to neutralize interstage mortality. Similarly, Petit et al [8] 1 
reported 8.3% interstage mortality after the implementation of SV-HMP at Texas Children’s Hospital, 2 
not significantly different from historic controls.  In this single-centre retrospective review 3 
encompassing 230 patients, including 34% non-Norwood palliations, two-thirds of the lethal 4 
interstage events presented as sudden death, with no apparent identifiable cause even at autopsy. 5 
Membership in the SV-HMP did not protect against interstage mortality [8].  This confirms the report 6 
by Hehir et al [2], who noted that the majority of interstage deaths after Norwood stage-one were 7 
sudden and unexpected events in infants with a history of arrhythmia.  Pulse-oximetry may be a useful 8 
tool to screen for shunt dysfunction, nevertheless shunt occlusion or thrombosis is not the leading 9 
cause of interstage mortality. Li et al. [11] reported that the mortality rate after Norwood palliation 10 
exceeds the rate of thrombosis with systemic-to-pulmonary shunts and suggested that a precipitating 11 
cause may be linked to coronary events. The inference is that no tool currently available can reliably 12 
screen and prevent sudden interstage death or adverse near-miss events. Therefore, a change in 13 
strategy for interstage management could be considered. Our study evaluates the preliminary 14 
experience with a different strategy after Norwood stage-one operation, the systematic in-hospital 15 
interstage program (in-HIP). In primis, our 93.3%±4.6% Norwood stage-one 30-day survival and 16 
80.9±7.0% aggregate transplant-free 4-year survival, favorably compares with the outcome reported 17 
at leading and high-volume Norwood centers, confirming Checchia’s findings [12]. The adoption of 18 
this strategy is based on the rationale that in-HIP facilitates escalation of care at its maximal speed 19 
and capacity. Since the experience of others essentially demonstrated the unpredictable and sudden 20 
nature of interstage mortality, the only tool left to impact on sudden death is speed of detection and 21 
reaction against adverse events, essentially like a hospital “red-code”. This is in line with the 22 
documented better outcome of in-hospital versus out-of-hospital management of cardiac arrest [13].  23 
In-HIP is not a completely new concept. Even in centers where HMP is a well-established practice, 24 
approximately 15-20% patients remain in-hospital until Norwood stage-two [3]. This strategy is 25 
generally selected for patients with “high-risk” profile, although the definition of “high-risk” after 26 
[14] 
 
Norwood stage-one is not easily discernible. Nevertheless, Rudd [3] reported an acceptable outcome 1 
for this “high risk” group who remained admitted until stage-two completion (83% survival), indirectly 2 
suggesting the efficacy of this strategy. The novel concept of our systematic in-HIP assumes that every 3 
patient after Norwood stage-one is, by definition, at high-risk for sudden death, because of the parallel 4 
model of Norwood circulation. This unavoidable substrate predisposes to serious sudden cardiac and 5 
extracardiac intercurrent events. Our study highlights two relevant findings. First, we could achieve a 6 
3.4% in-HIP mortality, lower than in most reported series. The second relevant finding is the 17.2% 7 
escalation of care that we observed during in-HIP. These incidents were abrupt, unexpected and 8 
required aggressive invasive management within minutes from PICU admission. Only one event was 9 
shunt-related, while the others were either respiratory accidents (requiring high-frequency oscillatory 10 
ventilation) or de-novo onset of atrial arrhythmias affecting tricuspid valve and ventricular function. 11 
These incidents occurred 2.5±1.2 months during interstage, while the patients were on apparent 12 
stable conditions in the ward. Typically, by this time the patients would have been at home under 13 
HMP. Very likely, had these events occurred at home, they would have been invariably fatal, in 14 
agreement with the experience of others on sudden death during interstage [8]. On the contrary, 15 
expeditious escalation of care with appropriate PICU management was life-saving. Our 17.2% 16 
escalation of care during in-HIP is not very different from the 18% interstage mortality reported by the 17 
SVR trial for the classic-Norwood operation [1]. Our provocative inference is that in-HIP converted 18 
interstage mortality in escalation of care, maximizing the chances of successful treatment of cardiac 19 
and extracardiac interstage incidents, ultimately controlling mortality. In agreement with other 20 
reports, unplanned operations or catheter reinterventions were frequent during interstage. A novel 21 
finding of this study is the identification of early development of aorto-pulmonary collaterals in 13.4% 22 
patients during interstage. We pursued an aggressive strategy to coil occlude these collaterals before 23 
Norwood stage-two, to avoid competitive flow and reduce ventricular volume overload, possibly 24 
affecting ventricular function and end-diastolic pressure. As a paired advantage, in-HIP facilitated the 25 
internal coordination for unplanned interventions, with minimal impact on daily scheduling.  The 26 
[15] 
 
awareness of resource utilization for in-HIP prompted anticipation of Norwood stage-two whenever 1 
feasible. Cardiac catheterization was routinely planned around 3 months of age and followed by 2 
Norwood stage-two around the age of 4 months (mean 138±9 days). In agreement with the experience 3 
of others, associated procedures with Norwood stage-two were frequently indicated, especially to 4 
augment the capacitance of the central pulmonary arteries. Our study suggests that the need for 5 
combined procedures at Norwood stage-two was significantly associated with the Norwood-Sano 6 
modification. The secondary end-point of our study was the evaluation of the sensitivity and specificity 7 
of speckle-tracking echocardiographic assessment of RV deformation in predicting death or transplant 8 
after Norwood stage-one operation. Norwood stage-one palliation generates a high output state and 9 
ventricular strain, which affects both systolic and diastolic function. Recently speckle-tracking 10 
echocardiography has been shown to be a reliable technique in the evaluation of RV deformation 11 
without any geometric assumption [14]. Moreover, using myocardial deformation parameters, RV 12 
function can be assessed without the influence of acute preload changes [15]. Some studies [14-16] 13 
have used speckle-tracking analysis to estimate RV performance in HLHS, nevertheless its correlation 14 
with clinical outcome has not been clearly elucidated.  This study indicates that a  LS of > 8.7% at one-15 
month after Norwood stage-one operation compared with basal pre-Norwood value is a powerful 16 
predictor of Norwood failure, defined as the combined outcome of death or transplantation during 17 
surgical staging. This finding could be a useful early indicator of outcome, independent of ventricular 18 
loading conditions, and we suggest it should be integrated in the routine echocardiographic 19 
longitudinal follow-up after Norwood operation. 20 
This study has several limitations. According to Checchia’s definition, the Brompton can be considered 21 
a high-volume Norwood center. However, despite the encouraging results, we recognize that this is 22 
preliminary experience and should be confirmed with time on a larger population scale. Only enduring 23 
with in-HIP will possibly corroborate these findings. Cost-effectiveness of this strategy is a legitimate 24 
concern for in-HIP. HLHS is resource-intensive disease. Hansen [17] calculated a median cost 25 
exceeding 360,000 $ for each 1-year HLHS survivor, reaching 390,000 $ for 5 year-survivors. ICU 26 
[16] 
 
accounted for over 40% of total costs. We cannot provide the exact budget details, however, we can 1 
state that in-HIP does not increase overall length of ICU-stay. Another criticism relates to possible 2 
alternative detection of the interstage events with appropriate HMP, therefore avoiding in-HIP. We 3 
could not detect any warning sign for the incidents that occurred during in-HIP. Only speed of reaction 4 
with escalation of care proved to be life-saving. The vulnerable nature of parallel circulation exposes 5 
all Norwood patients to the risk sudden death, with no reliable tool capable of secure screening in the 6 
experience of others. Considering the initial resource investment for HLHS management, a red-code 7 
type surveillance during in-HIP is justified for each Norwood survivor, in our opinion.   8 
In conclusion, our coordinated strategy including in-HIP allowed a 90.6±5.2% aggregate Norwood 9 
stage-one plus interstage survival, with an 80.9 ± 7.0% survival at 4 years. Mortality during in-HIP was 10 
almost neutralized (3.4%). In-HIP converted interstage mortality into escalation of care, which proved 11 
to be lifesaving in all cases.  A significant reduction of longitudinal strain (∆ LS of > 8.7%) at one-month 12 
after Norwood stage-one by speckle-tracking echocardiography was identified as a powerful early and 13 
load-independent parameter that could be helpful in predicting Norwood failure and should be 14 
integrated in the routine echocardiographic longitudinal evaluation of right ventricular function after 15 










Figure legend. 1 
Figure 1. Surgical strategy 2 
 3 
Figure 2a Interstage reintervention-free survival . Figure 2b. Interstage escalation of care -free survival  4 
 5 
Figure 3. Overall transplant-free survival and staging  6 
 7 
Figure 4. TAPSE, longitudinal strain and longitudinal strain-rate at specified time intervals 8 
  9 
Figure 5. Sensitivity and specificity of TAPSE and ∆ LS at one month after Norwood stage-one as 10 












References  1 
1) Ghanayem NS, Allen KR, Tabbutt S, Atz AM, Clabby ML, Cooper DS, et al Pediatric Heart 2 
Network Investigators. Interstage mortality after the Norwood procedure: results of the 3 
multicenter Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg. 2012;144:896– 4 
906. doi: 10.1016/j.jtcvs.2012.05.020.  5 
2) Hehir DA, Dominguez TE, Ballweg JA, Ravinshankar C, Marino BS, Bird GL, et al. Risk factors for 6 
interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variants. 7 
J Thorac Cardiovasc Surg 2008;136:94-99 8 
3) Rudd NA, Frommelt MA, Tweddell JS, Hehir DA, Mussatto KA, Frontier KD et al. Improving 9 
interstage survival after Norwood operation: outcomes from 10 years of home monitoring. J 10 
Thorac Cardiovasc Surg 2014; 148:1540-7 11 
4) Oster ME, Ehrlich A, King E, Petit CJ, Clabby ML, Smith S, et al.  Association of interstage home 12 
monitoring with mortality, readmissions, and weight gain. Circulation. 2015;132:502–508. 13 
5) Feinstein JA, Benson DW, Dubin AM, Cohen SM, Maxey DM, Mahle WT, et al. Hypoplastic Left 14 
Heart Syndrome: Current Considerations and Expectations. J Am Coll Cardiol. 2012 Jan 3; 59(1 15 
Suppl): S1–42 16 
6) Gardner MM, Mercer-Rosa L, Faerber J, DiLorenzo MP, Bates KE, Stagg A et al. Association of 17 
a home monitoring program with interstage and stage-2 outcomes. J Am Heart Assoc. 2019; 18 
8:e010783 19 
7) Siehr SL, Norris JK, Bushnell JA, Ramamoorthy C, Reddy VM, Hanley FL, et al. Home monitoring 20 
program reduces interstage mortality after the modified Norwood procedure. J Thorac 21 
Cardiovasc Surg. 2014;147:718–23.e1. doi: 10.1016/j.jtcvs.2013.04.006. 22 
8) Petit CJ, Fraser CD, Mattamal R, Slesnick TC,Cephus CE, Ocampo EC. The impact of a dedicated 23 
single-ventricle home-monitoring program on interstage somatic growth, interstage attrition, 24 
and 1-year survival. J Thorac Cardiovasc Surg 2011;142:1358-66 25 
[19] 
 
9) Furck AK, Uebing A, Hansen JH, Scheewe J, Jung O, Fischer G, Rickers C, Holland-Letz T, Kramer 1 
H-H. Outcome of the Norwood operation in patients with hypoplastic left heart syndrome: a 2 
12-year single-center survey. J Thorac Cardiovasc Surg. 2010;139:359–365 3 
10) Hanke SP, Joy B, Riddle E, Ravishankar C, Peterson LE, King E, et al. Risk factors for 4 
unanticipated readmissions during the interstage: a report from the National Pediatric 5 
Cardiology Quality Improvement Collaborative. Semin Thorac Cardiovasc Surg. 2017;28:803–6 
814. 7 
11) Li JS, Yow E, Berezny KY, Rhodes JF, Bokesch PM, Charpie JR et al. Clinical outcomes of 8 
palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic 9 
congenital heart disease: does aspirin make a difference? Circulation 2007;116:293-7 10 
12) Checchia PA, McCollegan J, Daher N, Kolovos N, Levy F, Markovitz B. The effect of surgical case 11 
volume on outcome after the Norwood procedure. J Thorac Cardiovasc Surg. 2005;129:754-9 12 
13) Moler FW,  Meert K, Donaldson AE., Nadkarni V, Brilli RJ,  Dalton HJ, et al. In-hospital versus 13 
out-of-hospital pediatric cardiac arrest: A multicenter cohort study. Crit Care Med. 2009 Jul; 14 
37(7): 2259–2267.  15 
14) Petko C, Uebing A, Furck A, Rickers C, Scheewe J, Kramer HH. Changes of right ventricular 16 
function and longitudinal deformation in children with hypoplastic left heart syndrome before 17 
and after the Norwood operation. J Am Soc Echocardiogr 2011;24:1226-32.  18 
15) Lin LQ, Conway J, Alvarez S, Goot B, Serrano-Lomelin J, Colen T et al. Reduced right ventricular 19 
fractional area change, strain and strain rate before bidirectional cavopulmonary anastomosis 20 
is associated with medium-term mortality for children with hypoplastic left heart syndrome. J 21 
Am Soc Echocardiogr 2018;31:832-42  22 
16) Menon SC, Minich LL, Casper TC, Puchalski MD, Hawkins JA, Tani LY. Regional myocardial 23 
dysfunction following Norwood with right ventricle to pulmonary artery conduit in patients 24 
with hypoplastic left heart syndrome. J Am Soc Echocardiogr 2011;24:826-33. 25 
[20] 
 
17) Hansen JE, Madsen NL, Bishop L, Morales DLS, Anderson JB. Longitudinal Health Care Cost in 1 


























Table 1. Anatomic details and associated lesions 1 
HLHS (24 patients)     2 
   3 
 Aortic atresia Aortic stenosis 
Mitral atresia 17 (71%) 2 (8%) 
Mitral stenosis 2  (8%) 3 (13%) 
 4 
Associated lesions 5 
  TAPVC-CS     1 6 
  PAPVC      1 7 
  intact or near-intact  muscular IAS  5 8 
  bilateral SVC     2 9 
  moderate-severe TR    2  10 
  11 
HLHS-variants (9 patients)  12 
    13 
 MS, AS (unicuspid),VSDs     3 14 
 unbalanced AVSD      2 15 
 DILV, malposed GA, sub-AS, arch hypoplasia   1  16 
 DORV, straddling AVV, sub-AS, arch hypoplasia   1 17 
 DORV, absent aortic valve     1  18 
 TGA, MS, PS, sub-PS      1 19 
 20 
Legenda: CS: coronary sinus; IAS: interatrial septum; GA: great arteries; AVV: atrioventricular valve; 21 










Table 2. Complications after Norwood stage-one 1 
 2 
            patients  management 3 
 4 
Left thalamic infarct    1  no clinical implications 5 
Neo-aortic valve incompetence   1  valve repair (reintervention) 6 
Aortic arch pseudoaneurysm  1  redo arch reconstruction 7 
Left diaphragmatic palsy  1  diaphragm plication 8 
Mediastinitis (Gram negative)  1  wash-out and betadine lavage 9 
Left vocal cord palsy   1  conservative 10 
















Table 3. Least-squares stepwise multivariable regression analysis for death-or-transplant at any time 1 




Independent variable coefficient Standard error (SE) t p-value 
 
 
𝑙𝑜𝑛𝑔𝑖𝑡𝑢𝑑𝑖𝑛𝑎𝑙 𝑠𝑡𝑟𝑎𝑖𝑛  
       
      0.089 
              
             0.002 
      
     3.321 
            
           0.0028 
 












Variables excluded by model 
             (p>0.05) 
 
    
Fractional area shortening     

















24 HLHS 9 HLHS-variants 
2 Norwood-Sano 
8 Norwood BT-shunt  5 Norwood BT-shunt 
2 comprehensive Norwood stage-2 
2 Hybrid palliation 
figure 1 Click here to access/download;Figure;figure 1 EJCTS-HLHS-
GM.docx


































































































80.9 ± 7.0 %
Figure 3 Click here to access/download;Figure;figure 3
final.pdf
Figure 4.  
TAPSE transplant-free survivors (0.7±0.1 cm)               TAPSE      death or transplant (0.5±0.05 cm) 
 
                                                                                                           p <0.01 
 
Longitudinal strain transplant-free survivors             Longitudinal strain death or transplant 
(-14.45 ± -1.9)                                                                             (-7.8 ± -0.3) 
 
                 p<0.01                              p<0.01 
 
Longitudinal strain rate: transplant free survival    Longitudinal strain rate: death or transplant 
(-0.9 ± -0.13)                                                                   (-0.5 ± -0.1) 
 













































1 2 3 4 5
Figure 4 Click here to access/download;Figure;Figure 4 EJCTS-HLHS-
GM (3).pdf



















TAPSE £ 5 mm
Figure 5a Click here to access/download;Figure;Figure
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